20 March 2020 - Deborah Wilkes
The US Consumer Healthcare Products Association (CHPA) has created the new position of vice president for scientific affairs and dietary supplements, Europe’s Committee for Herbal Medicinal Products (HMPC) has elected a new chair, and GlaxoSmithKline (GSK) has a new non-executive director.
US CHPA creates new position
The US CHPA has hired John Troup to fill the newly-created position of vice president for scientific affairs and dietary supplements.
The CHPA said Troup was a “natural products industry leader” with wide-ranging experience in the health, nutrition and dietary supplements sectors.
Troup joins the CHPA from Standard Process where he was vice president of clinical development, education, and innovation. Prior to that, he was the chief science officer at Metagenics. He has also worked for GNC, Novartis, Pfizer and Unilever.
The CHPA said Troup would lead strategy development and direct its work on dietary supplements issues, evaluating science, shaping policy, and collaborating with stakeholders.
“As the CHPA adopts a more holistic approach to self-care and expands its presence in the dietary supplement category, he will play an integral role in shaping and leading our association’s dietary supplements agenda,” commented Scott Melville, president and chief executive officer of the CHPA.
HMPC elects new chair
The European Medicines Agency’s (EMA’s) HMPC has elected Emiel van Galen as chair for a three-year mandate.
Van Galen is the head of department for Botanicals and Novel Foods at the Medicines Evaluation Board (CBG-MEB) in the Netherlands. He served as vice-chair of the HMPC from January 2017 to January 2020 and has been a member of the committee since 2004.
"HMPC has always been an important platform to harmonise the regulation of herbal medicinal products and substances in the European Union,” said van Galen. “As chair, I will strive to channel the passion and scientific expertise of HMPC members towards new initiatives to strengthen the safe use of herbal products in the European Union market and to address emerging issues in quality and manufacturing as a priority.”
GSK has new non-executive director
GSK has announced that Charles Bancroft will join its board as a non-executive director on 1 May 2020.
Bancroft recently retired from Bristol Myers Squibb (BMS) where he had worked since 1984. He was appointed chief financial officer in 2010; chief financial officer and executive vice president, Global Business Operations in 2016; and executive vice president and head of integration and strategy and business development in 2019.
He served as a member of the board of the Colgate-Palmolive Company from 2017 until March 2020.